{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-randomized-study-comparing-talquetamab-in-combination-with-pomalidomide-tal-p-talquetamab-in-combination-with-teclistamab-tal-tec-and-investigators-choice-of-either-elotuzumab-pomali\/#breadcrumbitem"}]}